Commentary - Journal of Clinical Cardiology (2021) Volume 2, Issue 2
Percutaneous Treatment of Mitral Valve Regurgitation: An Evolving Field
Alessandra Sala MD*, Ottavio Alfieri MD
Vita-Salute San Raffaele University, Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Milan, Italy
- *Corresponding Author:
- Alessandra Sala
Received date: March 08, 2021; Accepted date: June 23, 2021
Citation: Sala A, Alfieri O. Percutaneous Treatment of Mitral Valve Regurgitation: An Evolving Field. J Clin Cardiol. 2021;
Copyright: © 2021 Sala A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In the past two decades great interest has developed for less-invasive, percutaneous mitral valve (MV) repair strategies . This is mainly due to the increasing number of elderly patients with comorbidities and/or patients with left ventricular (LV) dysfunction, that are associated with a high surgical risk .
Whereas surgery still remains the gold-standard treatment for primary/degenerative mitral regurgitation (MR) [3,4], the optimal treatment for secondary mitral regurgitation remains controversial [5,6]. This leaves an
important window for transcatheter treatments.
Transcatheter mitral valve repair is, in fact, one of the greatest evolving fields in valvular heart interventions, with a continuous growing number of devices [7,8]. As previously underlined, the mitral valve apparatus is a complex anatomical and functional structure. Therefore, different devices have been developed capable of targeting the various components of the mitral valve: MV annulus, MV leaflets, and the subvalvular apparatus. This tries to mimic surgical mitral valve repair, either as single or combined procedures. The availability of such a widespectrum of devices allows to achieve a tailored approach for treating each patient: the right device according to the specific lesion .
Percutaneous edge-to-edge repair remains the most common percutaneous treatment used to address MR (>100,000 patients), and it is the only guidelinerecommended transcatheter procedure in selected patients [10-12]. In the past couple of years extensive
debate has risen regarding the role of MitraClip treatment in secondary mitral regurgitation and heart failure, in
patients that remained symptomatic despite optimal
medical therapy  (Figure 1A). Following what initially
appeared like contradictory results of two important
randomized clinical trials, MITRA-FR  and COAPT
, it became even more obvious that the percutaneous
edge-to-edge technology is beneficial in a specific subset
of patients, namely those with disproportionately severe
MR with respect to LV size and function , even though
specific echocardiographic parameters have not been
identified as independent prognostic values [17,18].
However, the use of the MitraClip device is not only limited by clinical features, but also by anatomical criteria, known as EVEREST Criteria. Recently, newer generations of MitraClip devices have been created, with wider arms, improved grasping and continuous left atrial pressure monitoring. Such innovations allow treatment of a wider range of challenging anatomies. Newer devices have also recently received CE mark approval (2019), such as the PASCAL system  (Figure 1B), which was designed in order to overcome some limitations of the MitraClip device, trying to expand patient eligibility for the edgeto- edge percutaneous repair . The device features larger paddles with a central spacer to maximize leaflet coaptation and the clasps allow for independent leaflet capture, together with smooth maneuvering of the whole system. Additional data on durability and the interplay with the MitraClip device need to be further investigated .
Another option in patients affected by leaflet prolapse is artificial chordal implantation, which can be performed transapically, off-pump, on a beating heart [22,23] (Figure 1C). Various devices have been created and prospective clinical trials are ongoing. Results show these procedures are safe, with minimal morbidity and mortality, an important reduction in MR and left ventricular reverse remodelling is obtained [24,25]. However, patient
selection, once more, seems the critical issue: such devices
provide focal support where the loop is implanted, resulting
in un-even coaptation along the prolapsing segment.
Therefore, the optimal candidate for this type of approach
is a patient with posterior leaflet prolapse, without marked
MV annulus dilation .
Up to one third of patients screened for a percutaneous leaflet repair technique are excluded due to unfavourable anatomy, including marked annular dilation. These devices further expand the transcatheter toolbox for MV treatment and are expected to improve overall results, either as single or combined procedures. They can be divided within two large categories: direct and indirect annuloplasty systems (Figure 1D and 1E). The former more closely reproduce surgical annuloplasty techniques, with more promising reported results . The latter instead take advantage of the favourable position of the coronary sinus with respect to the MV annulus . Such devices have been on the market for quite a long time, and despite the reproducible and not technically demanding delivery of the majority of them, effectiveness and applicability of such devices remains limited . However, interestingly enough, pivotal and randomized trials are being recently performed to assess outcomes of patients with secondary MR undergoing percutaneous annuloplasty procedures (REDUCE FMR Trial and ACTIVE Trial). Among many, the Cardioband device has been associated to leaflet repair or chordal replacement procedures to maximise MR reduction . The potential future of such combined
treatments still needs to be extensively studied.
Mitral valve replacement
Among the available percutaneous mitral valve treatment devices, MV replacement remains the least evolved. Both anatomical aspect and technical challenges strongly limit the wide-spread diffusion of such technologies. Proper anchoring and sealing of the prostheses to obtain stability remain important issues, together with the limited space the mitral valve and the left ventricular outflow tract with the high risk of protrusion and obstruction . Furthermore, the great majority of devices require a transapical access, and only very few are designed for a transvenous trans-septal delivery  (Figure 1F).
Treatment of MV regurgitation has generated great interest in the past decades, with an extremely broad range of treatment options. With this constantly growing toolbox, going from surgical interventions to percutaneous repair/replacement procedures or solely medical therapy, it is of utmost importance that patients affected by mitral regurgitation are evaluated and treated in dedicated heart-valve centres. The right choice of treatment for each individual patient is crucial, and is based on etiology, valve anatomy, valvular lesion, general conditions of the patient and patient’s will. All these aspects need to be evaluated by the Heart Team in order to offer the best possible treatment to every individual, gaining a patient-tailored approach . Therefore, “which treatment option to
In the future, percutaneous procedures will aim at combining various repair techniques in order to more strongly reproduce surgical techniques and try and obtain more effective and durable results. Regarding transcatheter MV replacement, technology will evolve and the number of transvenous trans-septal delivery systems will hopefully increase, further expanding treatment options.
Several trials regarding transcatheter devices for MV repair/replacement are still ongoing and will possibly shed some light on the best therapeutic option for each clinical scenario.
- Prendergast BD, Baumgartner H, Delgado V, Gérard
O, Haude M, Himmelmann A, et al. Transcatheter heart
valve interventions: Where are we? Where are we going?
Eur Heart J. 2019;40(5):422-440.
- Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Détaint
D, Vanoverschelde JL, et al. What are the characteristics
of patients with severe, symptomatic, mitral regurgitation
who are denied surgery? Eur Heart J. 2007;28(11):1358-
- Enriquez-Sarano M. Timing of mitral valve surgery.
Heart. 2002;87(1):79-85. doi:10.1136/heart.87.1.79
- Watt TMF, Brescia AA, Murray SL, et al. Degenerative
Mitral Valve Repair Restores Life Expectancy. Ann Thorac
- Acker MA, Parides MK, Perrault LP, Moskowitz AJ,
Gelijns AC, Voisine P, et al. Mitral-valve repair versus
replacement for severe ischemic mitral regurgitation. N
Engl J Med. 2014;370(1):23-32.
- Michler RE, Smith PK, Parides MK, Ailawadi G,
Thourani V, Moskowitz AJ, et al. Two-year outcomes
of surgical treatment of moderate ischemic mitral
regurgitation. N Engl J Med. 2016;374(20):1932-1941.
- Feldman T, Young A. Percutaneous approaches to
valve repair for mitral regurgitation. J Am Coll Cardiol.
- Nishimura RA, Vahanian A, Eleid M, Mack MJ. Mitral
valve disease. current management and future challenges.
- Alfieri O, Buzzatti N. Expansion of the treatment toolbox
for mitral regurgitation. Lancet. 2017;390(10096):722-
- Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm
C, Holm PJ, et al. 2017 ESC / EACTS Guidelines for the
management of valvular heart disease The Task Force
for the Management of Valvular Heart Disease of the
European Society of Cardiology ( ESC ) and the European.
Eur Heart J. 2017;38:2739-2791.
- Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J,
Smalling R, et al. Percutaneous mitral repair with the
MitraClip system: safety and midterm durability in the
initial EVEREST (Endovascular Valve Edge-to-Edge
REpair Study) cohort. J Am Coll Cardiol. 2009;54(8):686-
- Feldman T, Kar S, Elmariah S, Smart SC, Trento A,
Siegel RJ, et al. Randomized Comparison of Percutaneous
Repair and Surgery for Mitral Regurgitation 5-Year Results
of EVEREST II. J Am Coll Cardiol. 2015;66(25):2844-
- Puls M, Lubos E, Boekstegers P, von Bardeleben
RS, Ouarrak T, Butter C, et al. One-year outcomes
and predictors of mortality after MitraClip therapy in
contemporary clinical practice: Results from the German
transcatheter mitral valve interventions registry. Eur
Heart J. 2016;37(8):703-712.
- Obadia JF, Messika-Zeitoun D, Leurent G, Iung B,
Bonnet G, Piriou N, et al. Percutaneous repair or medical
treatment for secondary mitral regurgitation. N Engl J
- Stone GW, Lindenfeld J, Abraham WT, Kar S,
Lim DS, Mishell JM, et al. Transcatheter mitral-valve
repair in patients with heart failure. N Engl J Med.
- Grayburn PA, Sannino A, Packer M. Proportionate
and Disproportionate Functional Mitral Regurgitation: A
New Conceptual Framework That Reconciles the Results
of the MITRA-FR and COAPT Trials. JACC Cardiovasc
- Adamo M, Cani DS, Gavazzoni M, Taramasso M, Lupi
L, Fiorelli F, et al. Impact of disproportionate secondary
mitral regurgitation in patients undergoing edge-to-edge
percutaneous mitral valve repair. EuroIntervention.
- Lindenfeld J, Abraham WT, Grayburn PA, Kar S, Asch
FM, Lim DS, et al. Association of Effective Regurgitation
Orifice Area to Left Ventricular End-Diastolic Volume
Ratio With Transcatheter Mitral Valve Repair Outcomes:
A Secondary Analysis of the COAPT Trial. JAMA Cardiol.
- Praz F, Spargias K, Chrissoheris M, Büllesfeld L,
Nickenig G, Deuschl F, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for
patients with severe mitral regurgitation: a multicentre,
prospective, observational, first-in-man study. Lancet.
- Grasso C, Rubbio AP. The PASCAL transcatheter
mitral valve repair system for the treatment of mitral
regurgitation: Another piece to the puzzle of edge-to-edge
technique. J Thorac Dis. 2017;9(12):4856-4859.
- Lim DS, Kar S, Spargias K, Kipperman RM, O’Neill
WW, Ng MK, et al. Transcatheter Valve Repair for Patients
With Mitral Regurgitation: 30-Day Results of the CLASP
Study. JACC Cardiovasc Interv. 2019;12(14):1369-1378.
- Gammie JS, Wilson P, Bartus K, Gackowski A, Hung
J, D’Ambra MN, et al. Transapical beating-heart mitral
valve repair with an expanded polytetrafluoroethylene
cordal implantation device. Circulation. 2016;134(3):189-
- Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange
R, Schoenburg M, et al. Off-pump transapical implantation
of artificial neo-chordae to correct mitral regurgitation:
The tact trial (transapical artificial chordae tendinae)
proof of concept. J Am Coll Cardiol. 2014;63(9):914-919.
- Colli A, Manzan E, Aidietis A, Rucinskas K, Bizzotto
E, Besola L, et al. An early European experience with
transapical off-pump mitral valve repair with NeoChord
implantation. Eur J Cardio-thoracic Surg. 2018;54(3):460-
- Savic V, Pozzoli A, Gülmez G, Demir H, Batinkov N,
Kuwata S, et al. Transcatheter mitral valve chord repair.
Ann Cardiothorac Surg. 2018;6(7):731-740.
- Nickenig G, Schueler R, Dager A, Martinez
Clark P, Abizaid A, Siminiak T, et al. Treatment of
Chronic Functional Mitral Valve Regurgitation With a
Percutaneous Annuloplasty System. J Am Coll Cardiol.
- Bail DHL. Treatment of functional mitral regurgitation
by percutaneous annuloplasty using the Carillon Mitral
Contour System—Currently available data state. J Interv
- Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH,
Baldus S, Schueler R, et al. Transcatheter mitral valve repair
for functional mitral regurgitation using the Cardioband
system: 1 year outcomes. Eur Heart J. 2019;40(5):466-
- Latib A, Ancona MB, Ferri L, Montorfano M, Mangieri
A, Regazzoli D, et al. Percutaneous Direct Annuloplasty
With Cardioband to Treat Recurrent Mitral Regurgitation
After MitraClip Implantation. JACC Cardiovasc Interv.
- Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J,
Dagenais F, Paradis JM, Bernier M, et al. Early Experience
With Transcatheter Mitral Valve Replacement: A
Systematic Review. J Am Heart Assoc. 2019;8(17):e013332.
- Taramasso M, Gavazzoni M, Nickenig G, Maisano
F. Transcatheter mitral repair and replacement:
which procedure for which patient? EuroIntervention.
- Feldman T, Fernandes E, Levisay JP. Transcatheter
mitral valve repair/replacement for primary mitral
regurgitation. Ann Cardiothorac Surg. 2018;7(6):755-763.